339 related articles for article (PubMed ID: 26589840)
1. The therapeutic potential of microbial proteasome inhibitors.
Momose I; Kawada M
Int Immunopharmacol; 2016 Aug; 37():23-30. PubMed ID: 26589840
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Wang H; Yang Q; Dou QP; Yang H
Curr Protein Pept Sci; 2018 Feb; 19(4):358-367. PubMed ID: 28079010
[TBL] [Abstract][Full Text] [Related]
3. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
5. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
6. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R; Foster JB; Teachey DT
Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
[TBL] [Abstract][Full Text] [Related]
7. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
9. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
[TBL] [Abstract][Full Text] [Related]
10. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
11. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
12. Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
[TBL] [Abstract][Full Text] [Related]
13. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
14. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
15. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
16. New orally active proteasome inhibitors in multiple myeloma.
Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
[TBL] [Abstract][Full Text] [Related]
17. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
18. Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma.
Ubels J; Sonneveld P; van Vliet MH; de Ridder J
Clin Cancer Res; 2020 Nov; 26(22):5952-5961. PubMed ID: 32913136
[TBL] [Abstract][Full Text] [Related]
19. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]